Nasoryl M (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline Hydrochloride and Ipratropium Bromide, the active ingredients in Nasoryl M, are a nasal decongestant and an anticholinergic agent presented as a nasal spray for intranasal use. They act together to relieve nasal congestion and reduce secretions in patients with rhinitis. GNH USA supplies Nasoryl M as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasoryl M combines a decongestant and an anticholinergic to address conditions within the rhinitis spectrum. - Nasal congestion: reduces swelling of nasal mucosa to improve airflow. - Allergic rhinitis: limits reflex nasal secretions and eases blockage caused by allergens. - Non‑allergic rhinitis: diminishes mucosal edema and excessive discharge, supporting clearer breathing.

Nasoryl M may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing or mild epistaxis. - Bitter taste after administration. - Headache.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling, rash, or difficulty breathing. - Persistent hypertension or tachycardia. - Nasal ulceration or perforation with prolonged use. - Acute angle‑closure glaucoma exacerbation. - Cardiac arrhythmias in susceptible individuals.

Before using Nasoryl M, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Duration of use: limit to 3–5 days to avoid rebound congestion. - Pre‑existing conditions: avoid in patients with narrow‑angle glaucoma or severe hypertension. - Concomitant nasal surgery: postpone use until healing is complete. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nasoryl M can interact with other medications that affect vascular tone or cholinergic pathways.

Major Interactions (Avoid): - Systemic alpha‑adrenergic agonists: additive vasoconstrictive effects may raise blood pressure. - Other intranasal decongestants: risk of excessive vasoconstriction and rebound congestion. - Strong anticholinergic drugs: may increase anticholinergic burden leading to dry mouth or blurred vision.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may blunt systemic cardiovascular responses. - Antihypertensive agents: monitor blood pressure for potential elevation. - Monoamine oxidase inhibitors (MAOIs): observe for hypertensive episodes.